Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies
Adeno-associated virus (AAV)-derived vectors are currently the most common type of viral vectors used in gene therapy clinical trials. The presence of neutralizing antibodies (NAbs) against wild-type AAVs in the host body is one of the limitations for the successful use of AAV vectors. AAV capsid manipulation, by which recombinant vectors lose their ability to interact with NAbs, can help overcome this obstacle. Various methods can be used for this purpose, including directed evolution as well as conjugation of certain chemical groups to AAV epitopes. The present review concisely explains the use of AAV vectors in the clinic for gene therapy of some diseases, their limitations, and solutions to these limitations.
KeywordsGene therapy Adeno-associated vectors Neutralizing antibodies Capsid modification
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval statement
We confirm that the manuscript has not been submitted or previously published in whole or in part elsewhere and is not split up into several parts to increase the quantity of submissions (“salami-publishing”). The manuscript is not currently being considered for publication in another journal. In addition, no data have been fabricated or manipulated (including images) to support our conclusions and no data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). All authors, whose names appear on the submission, have been personally and actively involved in substantive work leading to the manuscript have, and all agreed to submit the manuscript to this journal.
Human and animal rights
The manuscript contains no studies with human participants or animals performed by any of the authors.
Formal consent is not required for this type of study.
- 2.Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science (80-) [Internet]. 2018;359.Google Scholar
- 3.Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. United States. 1965;149:754–6.Google Scholar
- 5.Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. United States. 1983;45:555–64.Google Scholar
- 6.Becerra SP, Koczot F, Fabisch P, Rose JA. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol. United States. 1988;62:2745–54.Google Scholar
- 7.Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol. United States. 2000;74:2777–85.Google Scholar
- 14.Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol. United States. 2004;78:3110–22.Google Scholar
- 17.Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood. United States. 2009;113:3682–9.Google Scholar
- 22.Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol. United States. 2005;79:9933–44.Google Scholar
- 25.Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol. United States. 1984;51:611–9.Google Scholar
- 28.Suzuki M, Bertin TK, Rogers GL, et al. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther [Internet]. 2013;21:796–805.Google Scholar
- 32.Tseng YS, Agbandje-McKenna M. Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors. Front Immunol [Internet]. 2014;5:9.Google Scholar
- 39.Wilson DS, Keefe AD. Random mutagenesis by PCR. Curr Protoc Mol Biol [Internet]. 2001;Chapter 8:Unit8 3.Google Scholar
- 43.Bartel M, Schaffer D, Buning H. Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol. Switzerland; 2011;2:204.Google Scholar
- 51.Tabebordbar M, Zhu K, Cheng JKW, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. United States. 2016;351:407–11.Google Scholar